Literature DB >> 26683093

Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells.

Manish S Hudlikar1,2, Xiuru Li1, Ivan A Gagarinov1,2, Nagesh Kolishetti1, Margreet A Wolfert1, Geert-Jan Boons3,4.   

Abstract

A major objective of nanomedicine is to combine in a controlled manner multiple functional entities into a single nanoscale device to target particles with great spatial precision, thereby increasing the selectivity and potency of therapeutic drugs. A multifunctional nanoparticle is described for controlled conjugation of a cytotoxic drug, a cancer cell targeting ligand, and an imaging moiety. The approach is based on the chemical synthesis of polyethylene glycol that at one end is modified by a thioctic acid for controlled attachment to a gold core. The other end of the PEG polymers is modified by a hydrazine, amine, or dibenzocyclooctynol moiety for conjugation with functional entities having a ketone, activated ester, or azide moiety, respectively. The conjugation approach allowed the controlled attachment of doxorubicin through an acid-labile hydrazone linkage, an Alexa Fluor dye through an amide bond, and a glycan-based ligand for the cell surface receptor CD22 of B-cells using strain promoted azide-alkyne cycloaddition. The incorporation of the ligand for CD22 led to rapid entry of the nanoparticle by receptor-mediated endocytosis. Covalent attachment of doxorubicin via hydrazone linkage caused pH-responsive intracellular release of doxorubicin and significantly enhanced the cytotoxicity of nanoparticles. A remarkable 60-fold enhancement in cytotoxicity of CD22 (+) lymphoma cells was observed compared to non- targeted nanoparticles.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  B-cell lymphoma; chemical biology; doxorubicin; drug delivery; nanoparticles

Mesh:

Substances:

Year:  2015        PMID: 26683093      PMCID: PMC4819120          DOI: 10.1002/chem.201503999

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  50 in total

Review 1.  A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Authors:  Arturo Molina
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

Review 2.  Nanoparticle delivery of cancer drugs.

Authors:  Andrew Z Wang; Robert Langer; Omid C Farokhzad
Journal:  Annu Rev Med       Date:  2011-09-01       Impact factor: 13.739

Review 3.  Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.

Authors:  Julien Nicolas; Simona Mura; Davide Brambilla; Nicolas Mackiewicz; Patrick Couvreur
Journal:  Chem Soc Rev       Date:  2013-02-07       Impact factor: 54.564

4.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

Authors:  Weihsu C Chen; Gladys C Completo; Darren S Sigal; Paul R Crocker; Alan Saven; James C Paulson
Journal:  Blood       Date:  2010-02-24       Impact factor: 22.113

Review 5.  Gold nanoparticles for biology and medicine.

Authors:  David A Giljohann; Dwight S Seferos; Weston L Daniel; Matthew D Massich; Pinal C Patel; Chad A Mirkin
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-26       Impact factor: 15.336

Review 6.  The convergence of synthetic organic and polymer chemistries.

Authors:  Craig J Hawker; Karen L Wooley
Journal:  Science       Date:  2005-08-19       Impact factor: 47.728

7.  Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin.

Authors:  Nathan R Zaccai; Katsumi Maenaka; Taeko Maenaka; Paul R Crocker; Reinhard Brossmer; Sørge Kelm; E Yvonne Jones
Journal:  Structure       Date:  2003-05       Impact factor: 5.006

8.  On-virus construction of polyvalent glycan ligands for cell-surface receptors.

Authors:  Eiton Kaltgrad; Mary K O'Reilly; Liang Liao; Shoufa Han; James C Paulson; M G Finn
Journal:  J Am Chem Soc       Date:  2008-03-15       Impact factor: 15.419

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

10.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Authors:  R Plummer; R H Wilson; H Calvert; A V Boddy; M Griffin; J Sludden; M J Tilby; M Eatock; D G Pearson; C J Ottley; Y Matsumura; K Kataoka; T Nishiya
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

View more
  6 in total

Review 1.  Smart pH-responsive nanomedicines for disease therapy.

Authors:  Jongyoon Shinn; Nuri Kwon; Seon Ah Lee; Yonghyun Lee
Journal:  J Pharm Investig       Date:  2022-05-09

2.  Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.

Authors:  Aiman Abu Ammar; Abed Nasereddin; Suheir Ereqat; Mary Dan-Goor; Charles L Jaffe; Eyal Zussman; Ziad Abdeen
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 3.  Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 4.  Coating Matters: Review on Colloidal Stability of Nanoparticles with Biocompatible Coatings in Biological Media, Living Cells and Organisms.

Authors:  Jonas Schubert; Munish Chanana
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

5.  Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Oncotarget       Date:  2019-10-22

Review 6.  Structure-Based Varieties of Polymeric Nanocarriers and Influences of Their Physicochemical Properties on Drug Delivery Profiles.

Authors:  Ranjit De; Manoj Kumar Mahata; Kyong-Tai Kim
Journal:  Adv Sci (Weinh)       Date:  2022-02-03       Impact factor: 16.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.